- Release Date: 05/03/15 10:23
- Summary: GENERAL: PEB: Pacific Edge adds India to its growing list of patents
- Price Sensitive: No
- Download Document 5.34KB
PEB 05/03/2015 10:23 GENERAL NOT PRICE SENSITIVE REL: 1023 HRS Pacific Edge Limited GENERAL: PEB: Pacific Edge adds India to its growing list of patents 5 March 2015 Pacific Edge adds India to its growing list of patents Pacific Edge has been granted patent protection in India for its Cxbladder technology. This comes several weeks after being granted patents for 38 countries in Europe for the same technology that enables the accurate and non-invasive detection of urothelial carcinomas. Pacific Edge Chief Executive Officer David Darling says India is the second largest country in terms of population. Its incidence rates of bladder cancer are reportedly also very high - not helped by the high levels of tobacco that continues to be consumed, which does increase the likelihood of bladder cancer. David Darling says: "While it is important for the Company to seek patent protection in key jurisdictions, our main focus continues to be building sales momentum in the US, the world's largest healthcare market, where we have just now started into our second year of commercial operations. Laboratory through-put is tracking to the company's expectations following an active direct sales and marketing program to clinicians and healthcare organisations. Pacific Edge Diagnostics USA has twelve dedicated sales executives operating in key geographic regions." Meanwhile Pacific Edge has been rapidly extending its portfolio of intellectual property based on its molecular diagnostic technology with the recent grant of patents in the US for the prognosis of melanoma, in Japan for the prognosis of colorectal cancer and in China for the detection of gastric cancer. "Extending and further developing our intellectual capital is essential for the long term commercial success of the Company and the creation of additional value for shareholders," David Darling says. Further developments of the Cxbladder technology are underway with the next product, Cxbladder Triage due to be released in the US this year after its successful launch in New Zealand. Cxbladder Triage allows clinicians to segregate patients who have presented to their healthcare provider with haematuria (blood in the urine, an early indicator of possible bladder cancer) who have a low probability of having urothelial carcinoma. The use of this new product - Cxbladder Triage provides upside and cost saving for the patient, the clinician and the healthcare system to exclude a significant proportion of these patients from having to have a full clinical work-up for bladder cancer that is both expensive and invasive. For more information contact: David Darling Chief Executive Officer Pacific Edge Ltd P: +64 (3) 479 5800 ABOUT PACIFIC EDGE Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests. It's first commercial product, Cxbladder Detect, is now being actively marketed to physicians and clinicians in New Zealand, Australia, and the USA through the company's wholly owned subsidiaries and selected commercial partners. www.pacificedge.co.nz www.pacificedgedx.com ABOUT Cxbladder Detect Cxbladder Detect is a proprietary, accurate molecular diagnostic test that enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of urine. Cxbladder Detect is commercially available in New Zealand, Australia and the USA. Cxbladder Detect is available in the USA and NZ as a laboroatory Developed Test (LDT) from the company's CLIA certified laboratories, providing physicians and clinicians with a quick, cost effective and accurate measure of the presence of the cancer, and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy. The Cxbladder Detect cancer detection test has been validated by a multicentre, international clinical study. www.cxbladder.com ABOUT Cxbladder Triage Cxbladder Triage is a novel molecular test that combines the power of the genomic biomarkers with extra phenotypic and clinical risk biomarkers to accurately identify and remove patients with haematuria who have a low probability of bladde cancer, from needing to have a full-urological work-up. This is a tool for use by clinicians and physicians in the primary evaluation and will result in a reduction of the number of patients needing an expensive and invasive work-up for urothelial cancer. www.cxbladder.com ABOUT BLADDER CANCER Globally, bladder cancer has the 9th highest incidence and the 4th highest incidence for men. One of the early symptoms of bladder cancer is the presence of blood in the urine, haematuria. People with haematuria often present to their general practitioner before being referred on to a urologist. Bladder cancer has a very high recurrence rate of approximately 50%-70% with up to 30% of these recurring as later stage tumours. However, bladder cancers are highly treatable, especially if detected in the early stages when there is a much higher probability of survival. Timely detection and regular surveillance and monitoring of this cancer is a key element of the clinical process and of the individual's annual healthcare plan. End CA:00261494 For:PEB Type:GENERAL Time:2015-03-05 10:23:35
- Forums
- NZX - By Stock
- PEB
- Ann: GENERAL: PEB: Pacific Edge adds India to its growing list of patents
Ann: GENERAL: PEB: Pacific Edge adds India to its growing list of patents
Featured News
Add PEB (NZSX) to my watchlist
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online